Executive Order 13939, signed on July 24, 2020, directed the Department of Health and Human Services to rewrite federal anti-kickback protections in pharmaceutical pricing. Specifically, the order instructed HHS to issue a safe harbor rule that would remove existing restrictions preventing rebates from flowing directly between pharmaceutical manufacturers, pharmacy benefit managers, and health plans during price negotiations. The legal mechanism invoked the anti-kickback statute itself, using an executive directive to reinterpret which financial arrangements would be protected from prosecution. HHS responded with a proposed rule in January 2021 that would have fundamentally altered how drug prices are negotiated in the American healthcare system.
The direct effects of this order ripple through multiple healthcare constituencies. Patients taking prescription medications face uncertain outcomes, as the intended price transparency could theoretically lower costs but also risks enabling new forms of opaque negotiation that benefit middlemen. Pharmacy benefit managers and pharmaceutical companies gained new latitude to structure rebate arrangements previously restricted under anti-kickback law. Health insurers obtained expanded authority to negotiate directly with manufacturers, though whether these savings reach patients depends on enforcement and market conditions. Medicare and Medicaid beneficiaries potentially see their drug formularies affected by altered negotiation dynamics.
This executive action fits within a broader Trump administration pattern of regulatory rollback in healthcare that prioritizes deregulation over patient protection. Where the related Title X program shift de-emphasized contraception access and the CDC vaccine overhaul stripped protective recommendations, this drug pricing order weakened safeguards ostensibly protecting against corrupt arrangements. However, unlike those actions, this order presented itself as market-liberating reform rather than restriction—a framing that masked the removal of consumer protections embedded in existing law.
Multiple legal challenges have impeded implementation of the proposed rule, with courts questioning whether the executive branch can unilaterally rewrite anti-kickback statute interpretations. The rule's real-world impact on patient drug prices remains undetermined as litigation continues, leaving the policy suspended in legal limbo rather than fully operational.
Executive Order on Reducing Drug Prices Through Eliminating Kickbacks
🏥 Healthcare · First Term (2017–2021) · 🤖 AI-categorized
Executive Order 13939 was signed on July 24, 2020, directing the Department of Health and Human Services to issue a safe harbor rule removing anti-kickback protections for rebates in drug pricing negotiations. The order aimed to increase price transparency by allowing pharmaceutical manufacturers, pharmacy benefit managers, and health plans to negotiate rebates directly. The confirmed effect was that HHS issued a proposed rule in January 2021 to modify anti-kickback statute safe harbors, though implementation faced legal challenges and the rule's real-world impact on patient drug prices remained subject to ongoing litigation.